COLOMBIA, CHILE AND PERU WILSON’S DISEASE TREATMENT MARKET ANALYSIS

Colombia, Chile and Peru Wilson’s Disease Treatment MarketSize and Trends

Colombia, Chile and Peru Wilson’s disease treatment market is estimated to be valued at US$ 799.4 thousand in 2022 and expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030).

Figure 1: Colombia, Chile and Peru Wilson’s Disease Treatment Market Share (%) Analysis, By Drugs, 2021

The increasing number of research and development activities to treat Wilson’s disease is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period. For instance, in September 2017, according to The Wilson Disease Association, patients with Wilson’s disease were being recruited by Wilson Disease Association, for a Pilot study to evaluate brain changes using magnetic resonance imaging (MRI). The study was sponsored by The Wilson Disease Association.

The increasing number of drug approvals from regulatory bodies is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period.

Increasing approvals from regulatory authorities are expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period. For instance, in May 2019, Amerigen Pharmaceuticals Limited., a generic pharmaceutical company, announced that Amerigen's Abbreviated New Drug Application (ANDA) for Penicillamine Capsules USP 250 mg has received final approval from the U.S. Food and Drug Administration (FDA). This is the first such ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine.

The increasing number of generic drug launches by the market players is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period.

Market players are focused on organic growth strategies such as drug launches, which is expected to drive the market growth over the forecast period. For instance, in February 2018, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of patients with Wilson’s disease who are intolerant of penicillamine.

Figure 2: Colombia, Chile and Peru Wilson’s Disease Treatment Market (US$ Thousand), by Country, 2021